Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01631136

Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer Clinical Trial

Official title:
Phase III Study Evaluating Two Strategies of Maintenance, One With Pemetrexed in Continuous Strategy and One According to the Response of Induction Chemotherapy, in Non Squamous Non Small Cell Lung Cancer of Advanced Stage

Clinical Trial Summary

In France, lung cancer is responsible for more than 30000 each year. Progress was made in treatment of lung cancer in the last five years due to targeted therapies and to strategical evolutions consisting in a best adjustment of treatments. Maintenance strategies is one of this strategical evolution. It is based on maintaining continuous therapeutical pression in order to preserve the therapeutical benefit obtained by the first line (induction chemotherapy). Several clinical trials showed that maintenance strategies increase the duration of controlled disease.

There is two types of maintenance strategies:

- Continuous maintenance : prolongation of the treatment initially associated with platin until progression

- Switch maintenance : introduction of a new treatment after the end of induction chemotherapy

The aim of this study is to compare two maintenance strategies

- A continuous maintenance by pemetrexed

- A switch maintenance or a continuous maintenance according to the response of induction chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01631136
Study type Interventional
Source Intergroupe Francophone de Cancerologie Thoracique
Contact
Status Completed
Phase Phase 3
Start date July 2012
Completion date November 30, 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT03326752 - Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC Phase 1
Completed NCT02157883 - Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Phase 1
Completed NCT00072631 - Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT02163733 - Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06107374 - Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG Phase 2
Completed NCT01802632 - AZD9291 First Time In Patients Ascending Dose Study Phase 1/Phase 2
Recruiting NCT06406166 - Lifei Xiaoji Wan in Treatment of Advanced NSCLC N/A
Terminated NCT04785365 - Long-Term Follow-Up Study of Patients Receiving ATL001 Phase 2
Recruiting NCT04032847 - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Phase 1/Phase 2
Recruiting NCT04239443 - Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer Phase 2
Completed NCT03452150 - D-0316 First Time in Patients Ascending Dose Study Phase 1
Completed NCT04144608 - Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT04755738 - Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer Phase 2
Completed NCT03652857 - Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Completed NCT03351361 - Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients Phase 3
Completed NCT02407327 - Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Active, not recruiting NCT02143466 - AZD9291 in Combination With Ascending Doses of Novel Therapeutics Phase 1
Recruiting NCT05004974 - Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT05777603 - Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04886401 - Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC